The feasibility of the CD271+ and CD271- mesenchymal stromal cell enrichment toward nucleus pulposus-like cells

• Published in: Folia histochemica et cytobiologica Vol. 55; no. 3; pp. 114 - 123
• Main Authors: Jezierska-Wozniak, Katarzyna, Barczewska, Monika, Habich, Aleksandra, Wojtacha, Pawel, Badowska, Wanda, Maksymowicz, Wojciech, Wojtkiewicz, Joanna
• Format: Journal Article
• Language: English
• Published: Poland Wydawnictwo Via Medica 01-01-2017
• Subjects: Aggrecan; Arthritis; Back pain; Biocompatibility; Biomarkers; Biomedical materials; Bone marrow; Cell differentiation; Chondrocytes; Chronic pain; Cloning; Collagen; Collagen (type II); Cytokines; Degeneration; Differentiation; Extracellular matrix; Gene expression; Glycosaminoglycans; Growth factors; Intervertebral discs; Mesenchymal stem cells; Mesenchyme; Nerves; Nuclei; Nuclei (cytology); Nucleus pulposus; Pain; Plastics; Population; Ribonucleic acid; RNA; Rodents; Scaffolds; Stem cells; Studies; Transplantation; chondrocyte-like cells; differentiation; CD271; intervertebral disc regeneration; mesenchymal stem cells
• ISSN: 0239-8508; 1897-5631
• DOI: 10.5603/FHC.a2017.0013

Factors promoting nerve cell ingrowth are considered responsible for chronic back pain resulting from the intervertebral disc degeneration (IDD). One of the recent exploratory IDD treatments is stem cell transplantation therapy. The CD271 (low-affinity nerve growth factor receptor) has been identified as a mark-er of the most homogeneous mesenchymal stem cell (MSC) subset. It is capable of promoting differentiation along adipogenic, osteogenic and chondrogenic lineages and producing significantly higher levels of cytokines as compared to the total population of plastic adherence-mesenchymal stem cells (PA-MSCs). We investigated the ability of CD271+ MSCs to differentiate into chondrocyte-like cells of the nucleus pulposus (NP) of intervertebral disc. We also examined CD271- MSCs, using PA-MSCs as a control cell population.
Bone marrow derived PA-MSCs and its two subsets, CD271- MSCs and CD271+ MSCs, were seeded in collagen scaffolds. After two weeks of growth in NP-differentiation medium, RNA was isolated from cells-scaffold constructs and was analyzed by q-PCR for expression of NP markers. Glycosaminoglycans were analyzed biochemically directly in cells-scaffold constructs.
Expression of NP markers - extracellular matrix components such as aggrecan, collagen type II and glycosaminoglycans on both RNA and the protein levels - was significantly higher in CD271- MSCs compared to the CD271+ MSCs and PA-MSCs cell populations.
CD271- MSCs may be superior candidates for NP restorative treatment compared to CD271+ MSCs and PA-MSCs due to their ability of expressing NP-supporting extracellular matrix components at levels higher than the other two studied MSC subsets.